Saturday 17 October 2026
Export ARQT’s income statement to Excel — free account
Arcutis Biotherapeutics, Inc.
ARQT Healthcare Biotechnology
Arcutis Biotherapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $376.1 million, up 91.3% from fiscal 2024. In the quarter to June 2026, revenue grew 59.3%, EPS grew 184.6%, free cash flow grew 228.0% and total debt was flat, each against the same quarter a year earlier. Revenue growth for three consecutive years, operating cash flow growth for three.
28.82
0.28
−0.96%
Follow ARQT
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | |
|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
4 | 4 | — | — | — | — | — | — | — |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — |
P/S ratio |
9.82 | 8.57 | 3.99 | 0.00 | — | — | — | — | — |
Altman Z-Score |
6.98 | 1.01 | (4.65) | (1.34) | — | — | — | — | — |
Altman Z″-Score (non-manufacturers) |
(3.68) | (7.30) | (8.30) | (2.98) | — | — | — | — | — |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — |
Beneish M-Score |
(1.52) | (0.63) | 10.15 | — | — | — | — | — | — |
P/Operating CF |
141.11 | (2,252.60) | (4.23) | (11.44) | — | — | — | — | — |
P/B ratio |
19.50 | 10.70 | 2.68 | 3.88 | — | — | — | — | — |
Price to Tangible BV |
21.15 | 11.38 | 2.89 | 4.02 | — | — | — | — | — |
EV/Sales |
9.53 | 8.46 | 2.81 | 0.00 | — | — | — | — | — |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — |
EV/Operating CF |
(636.90) | (14.83) | (0.68) | (2.33) | — | — | — | — | — |
EV/FCF |
(168.11) | (13.32) | (0.68) | (2.20) | — | — | — | — | — |
Quick Ratio |
2.83 | 3.72 | 6.40 | 11.09 | 11.67 | 12.68 | 19.34 | 19.06 | 4.94 |
Current Ratio |
3.17 | 4.15 | 7.08 | 11.57 | 12.09 | 12.96 | 20.33 | 19.12 | 5.52 |
Net Debt/EBITDA |
11.64 | 0.91 | 0.29 | 0.70 | 1.56 | 2.06 | 2.33 | 2.58 | 0.83 |
Debt/Assets |
25.17% | 30.73% | 59.12% | 44.17% | 17.83% | 1.66% | 0.29% | 0.00% | 0.00% |
Debt/Equity |
0.58 | 0.68 | 2.28 | 0.95 | 0.24 | 0.02 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.96 | 0.57 | 0.15 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
0.35 | 0.80 | 0.94 | 0.83 | 0.85 | 0.83 | 1.02 | 0.73 | 0.76 |
Capex/Depreciation |
(4.15) | 1.04 | 0.07 | 17.65 | (0.25) | (1.65) | 1.03 | 0.00 | — |
Interest Coverage |
(1.01) | (4.73) | (8.11) | (19.27) | — | — | — | — | — |
| (9.30%) | (113.76%) | (175.79%) | (122.80%) | (72.62%) | (131.99%) | 94.36% | 132.88% | 34.35% | |
| (4.13%) | (40.58%) | (66.31%) | (72.65%) | (58.42%) | (66.96%) | (53.12%) | (75.36%) | (18.13%) | |
ROIC |
(9.91%) | (221.85%) | (852.31%) | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(5.71%) | (54.74%) | (91.88%) | (77.58%) | (55.52%) | (49.84%) | (41.39%) | (39.76%) | (159.19%) |
Average Days of Receivables |
141.92 | 135.69 | 158.03 | 837.54 | 0.00 | 0.00 | — | — | — |
Research and Development Expense of Revenue |
20.49% | 38.88% | 185.51% | 4,949.40% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
73.01% | 116.71% | 310.61% | 3,313.19% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.03 | 0.03 | 0.02 | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
10.73% | 21.23% | 65.12% | 886.65% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Graham Net Nets |
0.05 | 0.09 | 0.33 | 0.24 | — | — | — | — | — |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — |
Earnings Yield |
(0.45%) | (8.33%) | (114.29%) | (38.25%) | — | — | — | — | — |
Free Cash Flow Yield |
(0.58%) | (7.41%) | (104.11%) | (33.65%) | — | — | — | — | — |
Revenue per Share |
2.96 | 1.62 | 0.86 | 0.07 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(0.04) | (0.93) | (3.56) | (4.68) | (3.53) | (3.17) | (23.24) | (11.36) | (5.43) |
Capex per Share |
(0.08) | (0.04) | (0.01) | (0.42) | (0.02) | (0.01) | (0.16) | 0.00 | 0.00 |
Free Cash Flow per Share |
(0.13) | (0.97) | (3.57) | (5.11) | (3.55) | (3.18) | (23.40) | (11.36) | (5.43) |
Cash per Share |
1.74 | 1.89 | 3.94 | 7.47 | 7.87 | 8.02 | 54.94 | 41.09 | 4.92 |
Shareholders Equity per Share |
1.49 | 1.30 | 1.28 | 3.81 | 6.03 | 7.59 | (35.28) | (19.35) | 0.00 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
1.49 | 1.30 | 1.28 | 3.81 | 6.03 | 7.59 | (35.28) | (19.35) | 0.00 |
Free Cash Flow |
(16.31) | (117.30) | (247.48) | (281.00) | (175.62) | (113.35) | (43.13) | (14.08) | (3.77) |
Working Capital |
281.39 | 254.81 | 283.76 | 399.60 | 369.45 | 270.22 | 101.24 | 48.43 | 3.13 |
Capital Expenditures |
(10.69) | (5.14) | (0.43) | (23.28) | (0.99) | (0.32) | (0.29) | — | — |
Net Current Asset Value |
167.74 | 144.47 | 77.73 | 197.71 | 292.30 | 265.18 | (65.57) | (23.99) | 3.82 |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — |
Capex to Sales |
0.03 | 0.03 | 0.01 | 6.32 | 0.00 | 0.00 | 0.00 | — | — |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — |
| Other line items | |||||||||
Depreciation/Fixed assets |
2.47 | (4.75) | (4.05) | (0.70) | 1.73 | 0.10 | (1.26) | 0.00 | — |
Cash ROIC |
(3.14%) | (23.78%) | (43.94%) | (34.32%) | (23.14%) | (20.19%) | (118.03%) | (52.26%) | (110.44%) |
Accounts Receivable Turnover |
3.43 | 3.98 | 3.48 | 0.84 | 0.00 | 0.00 | — | — | — |
Accounts Payable Turnover |
2.74 | 1.46 | 0.48 | 0.09 | 0.11 | 0.11 | 0.12 | 0.00 | 0.00 |
Inventory Turnover |
1.98 | 1.38 | 0.48 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Average Days of Payables |
124.61 | 271.35 | 877.70 | 4,273.02 | 3,517.49 | 5,727.69 | 2,629.87 | 0.00 | 0.00 |
Days of Inventory on Hand |
225.14 | 277.18 | 961.28 | 3,637.41 | 0.00 | 0.00 | 0.00 | — | — |
Average Receivables |
109.65 | 49.44 | 17.13 | 4.41 | 0.44 | 0.44 | — | — | — |
Average Payables |
13.37 | 13.11 | 10.41 | 8.09 | 7.25 | 4.27 | 1.60 | 1.17 | 1.17 |
Average Inventory |
18.58 | 13.83 | 10.32 | — | — | — | — | — | — |
Average Assets |
390.93 | 345.13 | 395.32 | 428.71 | 353.21 | 202.64 | 79.06 | 25.55 | 27.46 |
Average Common Equity |
173.51 | 123.10 | 149.12 | 253.63 | 284.15 | 102.80 | (44.51) | (14.49) | (14.49) |
Columns are period end dates